Meeting
2015 ASCO Annual Meeting
Analysis of CTLA4 expression on T regulatory cells in patients with advanced stage melanoma in the setting of high dose IL-2 (HDIL-2).
Authors
Maggie L. Diller
Emory University, Atlanta, GA
Maggie L. Diller , Cabell E. Eysmans , David H. Lawson , Keith A. Delman , Ragini Reiney Kudchadkar , Mandy Ford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9043)
DOI
10.1200/jco.2015.33.15_suppl.9043
Abstract #
9043
Poster Bd #
286
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response.
First Author: Ines Esteves Domingues Pires Da Silva
Poster
2014 ASCO Annual Meeting
Expansion of peptide-specific T cells from human melanoma-draining lymph nodes.
First Author: Madeleine Strohl
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini